We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 27 Jul 2015
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
Image: The AtomoRapid lateral flow immunoassay diagnostic platform (Photo courtesy of Atomo Diagnostics).
A novel rapid point-of-care assay for the diagnosis of Ebolavirus infection was introduced at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

BBI Solutions (Cardiff, United Kingdom), a biotech company that supplies a range of mouse monoclonal antibodies for detecting the Ebola virus, announced from its booth (3665) at the AACC Annual meeting that that it would soon release a rapid test for Ebola in association with the technology transfer company Ploughshare Innovations (Stockbridge, United Kingdom).

The test is built around the highly regarded Atomo Diagnostics (Sydney, Australia) lateral flow technology and provides a result in approximately 20 minutes. Five Ebola antibodies against the Zaire and Sudan strains of Ebolavirus have been tested successfully with this system. BBI Solutions also provides a panel comprising 13 different monoclonal antibodies, to the Zaire and Sudan strains.

The lateral flow test has already been evaluated in the field. In trials in Sierra Leone a 100% detection rate was achieved for 138 participants. At low positive levels the test achieved 100% sensitivity and 92% specificity, and at a high positive, 100% sensitivity and 97% specificity. This performance suggests that the BBI Solutions assay is potentially more sensitive and specific than other lateral flow or dipstick type assays currently available.

Leigh Thomas, chief commercial officer at BBI Solutions, said, “BBI has developed high performance lateral flow tests for some of the world’s leading diagnostic companies for over 25 years. Our expertise and flexibility has allowed us to quickly deploy a team and develop a rapid test in nine months which, based on field testing, promises to have an immediate and positive impact on the Ebola crisis. We are pleased that our test will meet an immediate need in the field and ultimately improve the lives of others.”

Related Links:
2015 AACC Annual Meeting & Clinical Lab Expo
BBI Solutions
Atomo Diagnostics


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Capillary Blood Collection Tube
IMPROMINI M3

Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
GLOBE SCIENTIFIC, LLC